These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21878529)

  • 21. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
    Yuan S; Qiao T; Chen W
    Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
    Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
    Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early growth response-1 is involved in foam cell formation and is upregulated by the TLR9-MyD88-ERK1/2 pathway.
    Kim JS; Park DW; Lee HK; Kim JR; Baek SH
    Biochem Biophys Res Commun; 2009 Dec; 390(2):196-200. PubMed ID: 19737531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
    Li N; Fan XG; Tang SE; Zhu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
    Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
    Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity.
    Putta MR; Zhu FG; Wang D; Bhagat L; Dai M; Kandimalla ER; Agrawal S
    Bioconjug Chem; 2010 Jan; 21(1):39-45. PubMed ID: 20020767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model.
    Kim IY; Yan X; Tohme S; Ahmed A; Cordon-Cardo C; Shantha Kumara HM; Kim SK; Whelan RL
    J Surg Res; 2012 May; 174(2):284-90. PubMed ID: 21324492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
    Zhang Z; Guo K; Schluesener HJ
    J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of CpG-oligodeoxynucleotides with Toll like receptor 9 induces apoptosis and modulates metaloproteinase-2 activity in human intestinal epithelium.
    Khorramizadeh MR; Hosseinzadeh S; Safavifar F; Saadat F; Aalizadeh N; Falak R; Jadali Z; Pezeshki M
    Iran J Allergy Asthma Immunol; 2007 Sep; 6(3):107-14. PubMed ID: 17893430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cancer immunotherapy with CpG-ODN].
    Carpentier AF
    Med Sci (Paris); 2005 Jan; 21(1):73-7. PubMed ID: 15639024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
    Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS
    Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of rabbit TLR9 by different CpG-ODN optimized for mouse and human TLR9.
    Liu J; Xu C; Liu YL; Matsuo H; Hsieh RP; Lo JF; Tseng PH; Yuan CJ; Luo Y; Xiang R; Chuang TH
    Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):443-51. PubMed ID: 22560893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs.
    Li Y; Cao H; Wang N; Xiang Y; Lu Y; Zhao K; Zheng J; Zhou H
    Vaccine; 2011 Mar; 29(11):2193-8. PubMed ID: 21036131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
    Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
    Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.
    Rayburn ER; Wang W; Zhang R; Wang H
    Int J Oncol; 2007 Jun; 30(6):1511-9. PubMed ID: 17487373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.
    Sommariva M; de Cesare M; Meini A; Cataldo A; Zaffaroni N; Tagliabue E; Balsari A
    J Transl Med; 2013 Jan; 11():25. PubMed ID: 23360557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
    Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
    Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.